List of Excipients in Branded Drug ADVICOR

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Physicians Total Care Inc	ADVICOR	niacin and lovastatin	54868-4807	FERRIC OXIDE RED
Physicians Total Care Inc	ADVICOR	niacin and lovastatin	54868-4807	FERRIC OXIDE YELLOW
Physicians Total Care Inc	ADVICOR	niacin and lovastatin	54868-4807	HYPROMELLOSES
Physicians Total Care Inc	ADVICOR	niacin and lovastatin	54868-4807	POLYETHYLENE GLYCOLS
Physicians Total Care Inc	ADVICOR	niacin and lovastatin	54868-4807	POLYSORBATE 80
Physicians Total Care Inc	ADVICOR	niacin and lovastatin	54868-4807	POVIDONE
Physicians Total Care Inc	ADVICOR	niacin and lovastatin	54868-4807	STEARIC ACID

Advicor Excipient Strategy and Commercial Opportunities

Last updated: October 1, 2026

Advicor is an extended-release combination tablet containing lovastatin and niacin. Its commercial opportunity is not a conventional branded-drug launch: the primary opportunity is a differentiated generic, 505(b)(2) product, or reformulated fixed-dose combination that improves niacin tolerability, controls release, and reduces manufacturing complexity. The largest technical risk is preserving the intended pharmacokinetic profile for both active ingredients while avoiding excipient-driven changes in dissolution, food effect, tablet robustness, and liver-safety exposure.

What is Advicor and what is its FDA status?

Advicor combines lovastatin, an HMG-CoA reductase inhibitor, with extended-release niacin in a single oral tablet. The product was developed to treat hypercholesterolemia and mixed dyslipidemia in patients requiring both LDL-cholesterol reduction and triglyceride or HDL-cholesterol management.

Attribute	Advicor
Active ingredients	Lovastatin and extended-release niacin
Dosage form	Oral extended-release tablet
FDA application	NDA 021366
Original sponsor	Kos Pharmaceuticals
Approved strengths	500 mg/20 mg, 750 mg/20 mg, 1,000 mg/20 mg, and 1,000 mg/40 mg niacin/lovastatin combinations
Primary use	Hypercholesterolemia and mixed dyslipidemia
Release design	Extended release, principally to moderate niacin exposure and improve tolerability
Current market position	Legacy product with limited or absent current branded commercial activity
Regulatory pathway for follow-on products	ANDA, if therapeutic equivalence and reference-product requirements can be met; otherwise 505(b)(2)

The FDA label identifies clinically important risks involving hepatotoxicity, myopathy, rhabdomyolysis, glucose intolerance, and niacin-related flushing. Those risks make release control a central product-quality issue rather than a secondary formulation preference.[1]

What excipients are relevant to Advicor formulation strategy?

Advicor’s excipient strategy must accommodate two active ingredients with different formulation requirements. Lovastatin is poorly water soluble and is sensitive to particle-size, wetting, and solid-state effects. Niacin is highly water soluble and requires controlled release to limit rapid systemic exposure and flushing.

Public product labeling identifies conventional tablet excipients, including diluents, binders, film-coating components, lubricants, and release-controlling polymers. The exact excipient composition and manufacturing process should be treated as product-specific because small changes in polymer grade, compression force, granulation moisture, or coating weight can alter dissolution behavior.[1]

Core excipient functions

Formulation function	Candidate excipient classes	Commercial purpose
Matrix formation	Hypromellose, hydroxypropyl cellulose, cellulose derivatives	Controls niacin hydration and diffusion
Dilution and tablet mass	Microcrystalline cellulose, lactose, calcium phosphate	Supports dose uniformity and compression
Binding	Povidone, copovidone, hydroxypropyl cellulose	Improves granule strength and tablet integrity
Wetting and dispersion	Surfactants, colloidal silicon dioxide, controlled particle-size diluents	Supports lovastatin dissolution
Lubrication	Magnesium stearate, sodium stearyl fumarate	Enables high-speed tableting
Film coating	Hypromellose, polyethylene glycol, titanium dioxide, iron oxides	Protects the tablet and supports identification
Moisture control	Low-moisture excipient systems and protective packaging	Limits degradation and dissolution drift

A polymer matrix is likely to be the principal release-control platform. The formulation must prevent dose dumping under fed conditions and maintain comparable release after exposure to alcohol, mechanical agitation, and gastrointestinal pH changes.

How should excipients be selected for an Advicor follow-on product?

The highest-value approach is a quality-by-design program that treats niacin release, lovastatin dissolution, and tablet mechanical performance as linked variables.

1. Separate the release mechanisms where possible

A bilayer or multiparticulate tablet could provide greater control than a single homogeneous matrix. One layer could control extended-release niacin, while a separate lovastatin layer could improve wetting and dissolution. This approach may reduce formulation compromise, but it increases manufacturing complexity and creates additional failure modes involving layer adhesion, weight variation, and scale-up.

A single-layer matrix is simpler and may have lower cost, but the same polymer network must accommodate a highly soluble active ingredient and a poorly soluble statin. That can create uneven release behavior across strengths.

2. Avoid excipients that increase niacin release variability

Highly soluble niacin can diffuse rapidly through hydrated hydrophilic matrices. Polymer viscosity, particle size, substitution pattern, and tablet porosity can materially change release. The development program should evaluate:

• Hypromellose viscosity grade
• Polymer concentration
• Compression force and tablet porosity
• Granule size distribution
• Lubricant concentration and blending time
• Coating weight and moisture transmission
• Dissolution across multiple pH conditions
• Alcohol-induced release acceleration

A low-substitution or hydrophobic polymer system may improve release control, but it can reduce robustness during scale-up. A hydrophilic matrix is generally easier to manufacture, but its performance depends more heavily on hydration and tablet structure.

3. Protect lovastatin dissolution

Lovastatin’s aqueous solubility is limited. Excipient selection should focus on wetting, dispersion, and control of the active’s solid state. Useful strategies include:

• Reduced and controlled lovastatin particle size
• Wetting agents at levels compatible with the release profile
• Colloidal silicon dioxide for flow and dispersion
• Carefully selected granulation conditions
• Avoidance of excessive hydrophobic lubricant coverage
• Solid-state characterization after granulation and compression

Lovastatin is also susceptible to conversion between lactone and hydroxy-acid forms. The formulation and process should control water activity, pH microenvironment, and storage conditions.

4. Evaluate food effects early

The Advicor label describes administration with food and identifies clinically relevant pharmacokinetic behavior for lovastatin and niacin.[1] A substitute formulation cannot rely only on dissolution similarity in standard aqueous media. Fed and fasted bioavailability studies, alcohol dose-dumping studies, and multiple discriminatory dissolution methods are likely to be important for regulatory positioning.

Excipient systems that produce strong food-dependent release may create a regulatory barrier even when the tablet meets routine dissolution specifications.

What formulation patents and manufacturing IP could protect a new Advicor product?

The strongest protectable assets would likely be narrow, technically defined claims rather than broad claims covering lovastatin plus niacin. Potential claim areas include:

1. A specific polymer matrix that controls niacin release across multiple strengths.
2. A bilayer or multilayer tablet separating lovastatin and niacin release functions.
3. A particle-size or solid-state specification for lovastatin.
4. A defined dissolution profile linked to reduced niacin peak exposure.
5. A manufacturing process controlling granulation moisture and tablet porosity.
6. A packaging system that maintains stability under high humidity.
7. A tablet architecture that reduces alcohol-induced dose dumping.
8. A method of reducing flushing while maintaining lipid-lowering efficacy.

A company pursuing this strategy should seek composition, process, and method-of-use protection in parallel. Formulation patents should claim measurable parameters, such as polymer viscosity, dissolution windows, active-to-polymer ratios, and release at defined time points. Broad claims based only on the presence of common excipients are vulnerable to invalidity and design-around.

When does Advicor lose exclusivity, and what is the generic-entry risk?

Advicor’s original small-molecule exclusivity and early patent protection are no longer the principal commercial barriers. The key question is whether any unexpired, enforceable formulation or method-of-use patents remain listed or otherwise relevant to a follow-on product.

Exclusivity issue	Commercial assessment
New chemical entity exclusivity	Expired
Original branded formulation exclusivity	Expired or commercially immaterial
Orange Book relevance	Must be assessed against current listing status for NDA 021366
Paragraph IV risk	Depends on any live listed patents and the reference-product pathway
Formulation design-around	Feasible, but dissolution and bioequivalence remain substantial hurdles
Biosimilar risk	None; Advicor is a small-molecule product
Generic substitution	Possible only after FDA approval and applicable state substitution rules

Because Advicor contains established small molecules, the principal barrier is not active-ingredient exclusivity. It is demonstrating equivalence for an extended-release combination product with a complex release profile. A generic sponsor may pursue an ANDA if FDA considers the reference product and regulatory record suitable. A 505(b)(2) strategy becomes more relevant if the sponsor changes the dosage form, release mechanism, strength architecture, or labeling basis.

What is the Orange Book and Paragraph IV outlook for Advicor?

The Orange Book determines whether listed patents could create a formal Paragraph IV certification issue for an ANDA. A Paragraph IV certification would allege that a listed patent is invalid, unenforceable, or not infringed. A qualifying Paragraph IV notice could trigger patent litigation and a 30-month stay under the Hatch-Waxman framework.

For Advicor, the commercial significance of an Orange Book review is likely lower than for an actively marketed blockbuster because:

• The product has an aged regulatory history.
• Original compound protection has expired.
• Any meaningful remaining protection would more likely involve formulation, dosing, or method-of-use claims.
• The limited current branded market reduces the value of prolonged litigation.
• A follow-on sponsor may be able to design around release-control claims.

A prospective applicant should distinguish between patents listed for the exact Advicor product and broader patents covering niacin extended-release technologies, statin formulations, manufacturing processes, or alternative fixed-dose combinations. Only the first category ordinarily creates direct Orange Book certification consequences.

What commercial opportunities exist for Advicor excipients?

Generic fixed-dose combination

The most direct opportunity is a lower-cost extended-release combination tablet. Commercial success would depend on three variables: reliable bioequivalence, competitive manufacturing cost, and a clear advantage over separate statin and niacin prescriptions.

The market is structurally difficult because statins are available generically and niacin use has declined as clinical practice shifted toward statins, ezetimibe, PCSK9 inhibitors, and triglyceride-focused products. The product may still have value in selected patients who need a single-tablet regimen or who cannot achieve a desired lipid profile with statin therapy alone.

Improved-tolerability formulation

A reformulated product could target lower flushing intensity, smoother niacin exposure, or improved gastrointestinal tolerability. Such a product would likely need clinical evidence beyond routine bioequivalence if it makes a meaningful therapeutic or tolerability claim.

Potential platforms include:

• Hydrophilic matrix tablets
• Multiparticulate capsules
• Coated pellets
• Bilayer tablets
• Osmotic or semipermeable delivery systems
• Fixed-dose combinations with alternative statins

A new formulation with a distinct release profile may fit a 505(b)(2) pathway more naturally than an ANDA.

Excipient supplier opportunity

Excipient manufacturers can pursue a platform strategy rather than an Advicor-specific product. The most relevant commercial products would be:

• High-viscosity hypromellose grades for niacin control
• Direct-compression excipient blends for high-dose tablets
• Low-moisture diluent systems
• Functionalized silica for statin dispersion
• Co-processing systems that improve content uniformity
• Film-coating systems with strong moisture protection
• Lubricant alternatives that reduce hydrophobic dissolution effects

The strongest supplier proposition would combine excipient performance data with formulation-development support, discriminatory dissolution methods, and scale-up experience.

How does Advicor compare with alternative lipid-lowering products?

Product strategy	Main advantage	Main weakness	Excipient opportunity
Advicor generic	Single-tablet combination	Complex release and limited niacin demand	Matrix and bioequivalence platform
Separate lovastatin plus niacin	Flexible dosing	Lower adherence and more tablets	Combination packaging
Statin plus ezetimibe	Stronger contemporary prescribing position	No niacin effect on HDL or triglycerides	Immediate-release combination technology
Statin plus PCSK9 therapy	Large LDL reduction	Injectable and expensive	Biologic delivery, not conventional excipients
Niacin monotherapy	Low cost	Flushing and limited current use	Modified-release and tolerability systems
Triglyceride-focused therapy	Targets a different lipid population	Less direct LDL benefit	Softgel and lipid-based delivery

What manufacturing and geographic barriers affect commercialization?

The main manufacturing risks are scale-up of extended-release tablets, control of polymer hydration, high-dose content uniformity, and stability under humidity. The product may require separate processing of lovastatin and niacin before final compression to avoid segregation or release interference.

Geographic opportunity is strongest in markets where:

• Fixed-dose oral combinations are reimbursed.
• Generic substitution is established.
• Niacin remains clinically accepted.
• Imported active ingredients and excipients are cost competitive.
• Regulatory agencies accept an established reference product or 505(b)(2)-type bridging strategy.

United States commercialization requires FDA approval and compliance with current good manufacturing practices. European and other jurisdictions may require separate bioequivalence and quality packages, particularly where the reference product is no longer marketed or where the formulation differs materially.

Key Takeaways

• Advicor is an extended-release lovastatin/niacin tablet, not a biologic; biosimilar risk is irrelevant.
• The commercial opportunity lies in a generic, reformulated, or improved-tolerability product rather than a new active ingredient.
• Niacin release control is the central formulation problem.
• Lovastatin requires separate attention to wetting, particle size, solid state, and lubricant effects.
• Hydrophilic matrices, bilayer tablets, and multiparticulate systems are the most credible formulation platforms.
• The original exclusivity position is aged; current risk depends on any live Orange Book listings and formulation patents.
• A generic ANDA may be possible, while a materially different delivery system may favor a 505(b)(2) strategy.
• Excipient suppliers can create value through polymer grades, low-moisture systems, direct-compression platforms, and formulation-development services.
• Market demand is constrained by the decline of niacin use and the availability of alternative lipid-lowering therapies.
• The strongest defensible IP would cover measurable release profiles, tablet architecture, manufacturing controls, and tolerability-linked performance.

FAQs

Is Advicor still sold in the United States?

Advicor is a legacy product with limited or absent current branded commercial activity. Its regulatory history remains relevant for follow-on development, but current market availability should be distinguished from the product’s historical FDA approval.

Can a generic company file an ANDA for Advicor?

Potentially. The feasibility depends on the current FDA reference-product status, applicable product-specific guidance, Orange Book listings, and the sponsor’s ability to demonstrate bioequivalence for both active ingredients and the extended-release profile.

Which excipient is most important for Advicor?

The release-controlling polymer is generally the most important excipient class because niacin is highly soluble and requires controlled release. Polymer grade, concentration, tablet porosity, and compression conditions can materially affect performance.

Would a bilayer Advicor tablet have stronger patent potential?

Potentially. A bilayer architecture can support claims directed to separation of lovastatin and niacin release functions, layer-specific excipient systems, and defined dissolution behavior. Patent strength would depend on novelty, non-obviousness, enablement, and measurable clinical or manufacturing advantages.

What is the largest commercial risk for a new Advicor product?

The largest risk is weak market demand relative to development cost. A technically successful product may still face limited uptake because statins are inexpensive, niacin use has declined, and alternative LDL- and triglyceride-lowering therapies are widely available.

References

1. U.S. Food and Drug Administration. (2008). Advicor (lovastatin and niacin extended-release) tablets: Prescribing information. FDA. https://www.accessdata.fda.gov
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA. https://www.accessdata.fda.gov/scripts/cder/ob/
3. U.S. Food and Drug Administration. (2023). Guidance for industry: ANDAs for certain highly purified synthetic peptides. FDA.
4. U.S. Food and Drug Administration. (2017). Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms. FDA.
5. U.S. Food and Drug Administration. (2015). Q8(R2) pharmaceutical development. International Council for Harmonisation.
6. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP.